Arcturus Therapeutics, Inc.

This early-stage trial tested a new self-amplifying mRNA vaccine (ARCT-2304) designed to protect against pandemic influenza. 212 healthy adults aged 18-80 received either two doses of the experimental vaccine or one dose of a licensed flu vaccine plus placebo. Researchers monitor…

This study tested a new type of COVID-19 vaccine (ARCT-2303) in adults who had already received a COVID-19 vaccine. Some participants got the COVID-19 vaccine at the same time as the seasonal flu shot, while others got it alone. The goal was to see if the combination was safe and…

This study tested three new self-amplifying RNA vaccines against COVID-19 in 72 healthy adults, some already vaccinated and some not. The goal was to check safety and how well the vaccines boost the immune system. Results help decide which vaccine candidates to study further.

This early-stage trial tested a new type of flu vaccine called ARCT-2138, which uses self-amplifying mRNA technology to potentially provide stronger and longer-lasting protection. The study involved 139 healthy adults aged 18-49 and 65-85, who received either the experimental vac…